Puma Biotechnology (PBYI) Debt to Equity (2019 - 2025)
Puma Biotechnology (PBYI) has disclosed Debt to Equity for 7 consecutive years, with $0.17 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Debt to Equity fell 76.26% year-over-year to $0.17, compared with a TTM value of $0.17 through Dec 2025, down 76.26%, and an annual FY2025 reading of $0.17, down 76.26% over the prior year.
- Debt to Equity was $0.17 for Q4 2025 at Puma Biotechnology, down from $0.29 in the prior quarter.
- Across five years, Debt to Equity topped out at $13.63 in Q1 2022 and bottomed at -$39.69 in Q4 2021.
- Average Debt to Equity over 5 years is $0.35, with a median of $1.91 recorded in 2023.
- Peak annual rise in Debt to Equity hit 456.65% in 2021, while the deepest fall reached 140.28% in 2021.
- Year by year, Debt to Equity stood at -$39.69 in 2021, then skyrocketed by 111.46% to $4.55 in 2022, then crashed by 59.01% to $1.86 in 2023, then crashed by 60.97% to $0.73 in 2024, then tumbled by 76.26% to $0.17 in 2025.
- Business Quant data shows Debt to Equity for PBYI at $0.17 in Q4 2025, $0.29 in Q3 2025, and $0.43 in Q2 2025.